Navigation Links
Cerecor Raises $22 Million Series A Financing

BALTIMORE, April 4, 2012 /PRNewswire/ -- Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, announced today that it has raised over US$22 million in an overallotment of its January 2012 Series A preferred stock financing. The offering, which was placed with accredited investors including members of Cerecor's Board of Directors, significantly exceeded the offering maximum of US$15 million.  Maxim Group, LLC of New York, NY acted as placement agent in connection with the offering.

(Logo: )

"The completion of this financing is an important step in bringing our lead product, FP01 for the treatment of chronic and acute cough, to the market and to support our early preclinical efforts in cognition and schizophrenia. We are delighted by the enthusiastic response to our offering, as it confirms the quality of our Company, its product pipeline and our founding team," stated Blake M. Paterson, M.D., Co-founder & CEO of Cerecor.

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization.  

For More Information, contact:
John Dierkes
Kennedy Advisors 
(410) 935-9334

SOURCE Cerecor Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
4. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
5. Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
6. Dyadic International Raises $3 Million in Private Placement of Convertible Notes
7. Creabilis Raises €15M ($20M) in Series B Fundraising Round
8. SironRX Therapeutics Raises $3.4 Million Series A
9. PPTA Praises Legislation That Protects the Treatment of Rare Diseases
10. Evergreen Foundation Gala Raises $1.16 Million for Cancer Care, Kicks off Capital Campaign
11. FireFly® Toothbrush Facebook Campaign Raises Funds for Smile Train
Post Your Comments:
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
Breaking Biology Technology:
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):